EMBO Mol Med Volume: 14 Page(s): e09824
04/07/2022 Authors: Marino M; Zhou L; Rincon MY; Callaerts-Vegh Z; Verhaert J; Wahis J; Creemers E; Yshii L; Wierda K; Saito T
Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimer's Disease Like Amyloid Pathology in APP-TgCRND8 Mice.
Int J Mol Sci Volume: 23
03/19/2022 Authors: Aravindraja C; Sakthivel R; Liu X; Goodwin M; Veena P; Godovikova V; Fenno JC; Levites Y; Golde TE; Kesavalu L
04/07/2022 Authors: Marino M; Zhou L; Rincon MY; Callaerts-Vegh Z; Verhaert J; Wahis J; Creemers E; Yshii L; Wierda K; Saito T
Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimer's Disease Like Amyloid Pathology in APP-TgCRND8 Mice.
Int J Mol Sci Volume: 23
03/19/2022 Authors: Aravindraja C; Sakthivel R; Liu X; Goodwin M; Veena P; Godovikova V; Fenno JC; Levites Y; Golde TE; Kesavalu L
Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse A plaque pathology when injected into newborn mouse hosts.
Free Neuropathol Volume: 3
01/11/2022 Authors: Moore BD; Levites Y; Xu G; Hampton H; Adamo MF; Croft CL; Futch HS; Moran C; Fromholt S; Janus C
Il-10 signaling reduces survival in mouse models of synucleinopathy
npj Parkinson's Disease Volume: 7
12/01/2021 Authors: Cockey SG; McFarland KN; Koller EJ; Brooks MMT; Gonzalez De La Cruz E; Cruz PE; Ceballos-Diaz C; Rosario AM; Levites YR; Borchelt DR
Complexes of Soluble a-Synuclein and Amyloid-beta with Their Cognate Antibodies Activate the NLRP3 Inflammasome in hiPSC-Derived Microglia
Volume: 90 Page(s): S169 - S169
10/01/2021 Authors: Trudler D; Nazor KL; Eisele YS; Grabauskas T; Dolatabadi N; Parker J; Sultan A; Zhong Z; Goodwin MS; Levites Y
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease.
Alzheimers Dement Volume: 17 Page(s): 984 - 1004
06/01/2021 Authors: Li H-D; Funk CC; McFarland K; Dammer EB; Allen M; Carrasquillo MM; Levites Y; Chakrabarty P; Burgess JD; Wang X
Modulating innate immune activation states impacts the efficacy of specific A immunotherapy.
Mol Neurodegener Volume: 16 Page(s): 32
05/06/2021 Authors: Levites Y; Funk C; Wang X; Chakrabarty P; McFarland KN; Bramblett B; O'Neal V; Liu X; Ladd T; Robinson M
Soluble -synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia.
Proc Natl Acad Sci U S A Volume: 118
04/13/2021 Authors: Trudler D; Nazor KL; Eisele YS; Grabauskas T; Dolatabadi N; Parker J; Sultan A; Zhong Z; Goodwin MS; Levites Y
Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes.
Mol Ther Volume: 29 Page(s): 859 - 872
02/03/2021 Authors: Goodwin MS; Sinyavskaya O; Burg F; O'Neal V; Ceballos-Diaz C; Cruz PE; Lewis J; Giasson BI; Davies P; Golde TE
Biophysical characteristics of lipid-induced A oligomers correlate to distinctive phenotypes in transgenic mice.
FASEB J Volume: 35 Page(s): e21318
02/01/2021 Authors: Saha J; Dean DN; Dhakal S; Stockmal KA; Morgan SE; Dillon KD; Adamo MF; Levites Y; Rangachari V
A40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate A42 toxicity in Drosophila.
Alzheimers Res Ther Volume: 12 Page(s): 132
10/17/2020 Authors: De Mena L; Smith MA; Martin J; Dunton KL; Ceballos-Diaz C; Jansen-West KR; Cruz PE; Dillon KD; Rincon-Limas DE; Golde TE
Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models.
Cell Rep Volume: 32 Page(s): 107908
07/14/2020 Authors: Wan Y-W; Al-Ouran R; Mangleburg CG; Perumal TM; Lee TV; Allison K; Swarup V; Funk CC; Gaiteri C; Allen M
Fyn depletion ameliorates tauP301L-induced neuropathology.
Acta Neuropathol Commun Volume: 8 Page(s): 108
07/14/2020 Authors: Liu G; Fiock KL; Levites Y; Golde TE; Hefti MM; Lee G
Diversity in A deposit morphology and secondary proteome insolubility across models of Alzheimer-typeamyloidosis.
Acta Neuropathol Commun Volume: 8 Page(s): 43
04/06/2020 Authors: Xu G; Fromholt SE; Chakrabarty P; Zhu F; Liu X; Pace MC; Koh J; Golde TE; Levites Y; Lewis J
Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS.
Mol Neurodegener Volume: 15 Page(s): 15
03/02/2020 Authors: Goodwin MS; Croft CL; Futch HS; Ryu D; Ceballos-Diaz C; Liu X; Paterno G; Mejia C; Deng D; Menezes K
Neurite orientation dispersion and density imaging reveals white matter and hippocampal microstructure changes produced by Interleukin-6 in the TgCRND8 mouse model of amyloidosis.
Neuroimage Volume: 202 Page(s): 116138
11/15/2019 Authors: Colon-Perez LM; Ibanez KR; Suarez M; Torroella K; Acuna K; Ofori E; Levites Y; Vaillancourt DE; Golde TE; Chakrabarty P
Intra- and extracellular -amyloid overexpression via adeno-associated virus-mediated gene transfer impairs memory and synaptic plasticity in the hippocampus.
Sci Rep Volume: 9 Page(s): 15936
11/04/2019 Authors: Forner S; Martini AC; Prieto GA; Dang CT; Rodriguez-Ortiz CJ; Reyes-Ruiz JM; Trujillo-Estrada L; da Cunha C; Andrews EJ; Phan J
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes.
J Exp Med Volume: 216 Page(s): 2479 - 2491
11/04/2019 Authors: Futch HS; McFarland KN; Moore BD; Kuhn MZ; Giasson BI; Ladd TB; Scott KA; Shapiro MR; Nosacka RL; Goodwin MS
AAV-mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer's disease mouse model
Volume: 30 Page(s): A95 - A95
11/01/2019 Authors: Rincon MY; Zhou L; Marneffe C; Voytyuk I; Wouters Y; Dewilde M; Duque SI; Vincke C; Levites Y; Golde TE
Comparative analyses of the in vivo induction and transmission of -synuclein pathology in transgenic mice by MSA brain lysate and recombinant -synuclein fibrils.
Acta Neuropathol Commun Volume: 7 Page(s): 80
05/20/2019 Authors: Dhillon J-KS; Trejo-Lopez JA; Riffe C; Levites Y; Sacino AN; Borchelt DR; Yachnis AY; Giasson BI
Magnetic resonance-based axonal microstructure measures are differentially modulated by interleukin-6 in amyloid expressing TgCRND8 mice
Volume: 33
04/01/2019 Authors: Febo M; Colon-Perez LM; Ibanez KR; Suarez MR; Acuna KR; Levites Y; Ofori E; Vaillancourt DE; Golde TE; Chakrabarty P
rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies.
J Exp Med Volume: 216 Page(s): 539 - 555
03/04/2019 Authors: Croft CL; Cruz PE; Ryu DH; Ceballos-Diaz C; Strang KH; Woody BM; Lin W-L; Deture M; Rodrguez-Lebrn E; Dickson DW
Short A peptides attenuate A42 toxicity in vivo.
J Exp Med Volume: 215 Page(s): 283 - 301
01/02/2018 Authors: Moore BD; Martin J; de Mena L; Sanchez J; Cruz PE; Ceballos-Diaz C; Ladd TB; Ran Y; Levites Y; Kukar TL
Designing antibodies against LRRK2-targeted tau epitopes.
PLoS One Volume: 13 Page(s): e0204367
01/01/2018 Authors: Hamm M; Ladd TB; Levites Y; Golde TE; Giasson BI; Lewis J
Novel monoclonal antibodies targeting the microtubule-binding domain of human tau.
PLoS One Volume: 13 Page(s): e0195211
01/01/2018 Authors: Croft CL; Moore BD; Ran Y; Chakrabarty P; Levites Y; Golde TE; Giasson BI
Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
Acta Neuropathol Commun Volume: 5 Page(s): 58
07/31/2017 Authors: Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
Strain-specific Fibril Propagation by an A Dodecamer.
Sci Rep Volume: 7 Page(s): 40787
01/18/2017 Authors: Dean DN; Das PK; Rana P; Burg F; Levites Y; Morgan SE; Ghosh P; Rangachari V
Holdase activity of secreted Hsp70 masks amyloid-42 neurotoxicity in Drosophila.
Proc Natl Acad Sci U S A Volume: 113 Page(s): E5212 - E5221
08/30/2016 Authors: Fernandez-Funez P; Sanchez-Garcia J; de Mena L; Zhang Y; Levites Y; Khare S; Golde TE; Rincon-Limas DE
Deficits in hippocampal-dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis.
Hippocampus Volume: 26 Page(s): 455 - 471
04/01/2016 Authors: Montgomery KS; Edwards G; Levites Y; Kumar A; Myers CE; Gluck MA; Setlow B; Bizon JL
Anti-A single-chain variable fragment antibodies exert synergistic neuroprotective activities in Drosophila models of Alzheimer's disease.
Hum Mol Genet Volume: 24 Page(s): 6093 - 6105
11/01/2015 Authors: Fernandez-Funez P; Zhang Y; Sanchez-Garcia J; de Mena L; Khare S; Golde TE; Levites Y; Rincon-Limas DE
IFN- promotes phosphorylation without affecting mature tangles.
FASEB J Volume: 29 Page(s): 4384 - 4398
10/01/2015 Authors: Li A; Ceballos-Diaz C; DiNunno N; Levites Y; Cruz PE; Lewis J; Golde TE; Chakrabarty P
A human monoclonal IgG that binds a assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.
J Neurosci Volume: 35 Page(s): 6265 - 6276
04/22/2015 Authors: Levites Y; O'Nuallain B; Puligedda RD; Ondrejcak T; Adekar SP; Chen C; Cruz PE; Rosario AM; Macy S; Mably AJ
Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice.
Mol Ther Volume: 23 Page(s): 53 - 62
01/01/2015 Authors: Ayers JI; Fromholt S; Sinyavskaya O; Siemienski Z; Rosario AM; Li A; Crosby KW; Cruz PE; DiNunno NM; Janus C
Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction.
J Vis Exp Page(s): 51863
09/15/2014 Authors: Kim J-Y; Grunke SD; Levites Y; Golde TE; Jankowsky JL
Induction of CNS -synuclein pathology by fibrillar and non-amyloidogenic recombinant -synuclein.
Acta Neuropathol Commun Volume: 1 Page(s): 38
07/17/2013 Authors: Sacino AN; Brooks M; McGarvey NH; McKinney AB; Thomas MA; Levites Y; Ran Y; Golde TE; Giasson BI
Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy.
Acta Neuropathol Volume: 126 Page(s): 39 - 50
07/01/2013 Authors: Clippinger AK; D'Alton S; Lin W-L; Gendron TF; Howard J; Borchelt DR; Cannon A; Carlomagno Y; Chakrabarty P; Cook C
Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo.
Eur J Neurosci Volume: 37 Page(s): 1203 - 1220
04/01/2013 Authors: Kim J-Y; Ash RT; Ceballos-Diaz C; Levites Y; Golde TE; Smirnakis SM; Jankowsky JL
Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.
PLoS One Volume: 8 Page(s): e67680
01/01/2013 Authors: Chakrabarty P; Rosario A; Cruz P; Siemienski Z; Ceballos-Diaz C; Crosby K; Jansen K; Borchelt DR; Kim J-Y; Jankowsky JL
Overlapping profiles of A peptides in the Alzheimer's disease and pathological aging brains.
Alzheimers Res Ther Volume: 4 Page(s): 18
05/23/2012 Authors: Moore BD; Chakrabarty P; Levites Y; Kukar TL; Baine A-M; Moroni T; Ladd TB; Das P; Dickson DW; Golde TE
A alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo.
Nat Commun Volume: 3 Page(s): 1009
01/01/2012 Authors: Cao L; Schrank BR; Rodriguez S; Benz EG; Moulia TW; Rickenbacher GT; Gomez AC; Levites Y; Edwards SR; Golde TE
Bispecific tandem single chain antibody simultaneously inhibits -secretase and promotes -secretase processing of APP.
J Alzheimers Dis Volume: 28 Page(s): 961 - 969
01/01/2012 Authors: Boddapati S; Levites Y; Suryadi V; Kasturirangan S; Sierks MR
Inhibiting -secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
J Mol Biol Volume: 405 Page(s): 436 - 447
01/14/2011 Authors: Boddapati S; Levites Y; Sierks MR
Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition.
FASEB J Volume: 24 Page(s): 548 - 559
02/01/2010 Authors: Chakrabarty P; Jansen-West K; Beccard A; Ceballos-Diaz C; Levites Y; Verbeeck C; Zubair AC; Dickson D; Golde TE; Das P
Quantitative and mechanistic studies of Abeta immunotherapy.
CNS Neurol Disord Drug Targets Volume: 8 Page(s): 31 - 49
03/01/2009 Authors: Golde TE; Das P; Levites Y
Generating differentially targeted amyloid- specific intrabodies as a passive vaccination strategy for alzheimer's disease
Molecular Therapy Volume: 17 Page(s): 2031 - 2040
01/01/2009 Authors: Sudol KL; Mastrangelo MA; Narrow WC; Frazer ME; Levites YR; Golde TE; Federoff HJ; Bowers WJ
BRI2 (ITM2b) inhibits Abeta deposition in vivo.
J Neurosci Volume: 28 Page(s): 6030 - 6036
06/04/2008 Authors: Kim J; Miller VM; Levites Y; West KJ; Zwizinski CW; Moore BD; Troendle FJ; Bann M; Verbeeck C; Price RW
Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis.
J Neurosci Volume: 27 Page(s): 7141 - 7153
07/04/2007 Authors: Laifenfeld D; Patzek LJ; McPhie DL; Chen Y; Levites Y; Cataldo AM; Neve RL
Erratum: Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid amyloid 40, and amyloid 42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice (Journal of Neuroscience (2006) 26, 46 (11923-11928))
Journal of Neuroscience Volume: 26
12/06/2006 Authors: Levites Y; Jansen K; Smithson LA; Dakin R; Holloway VM; Das P; Golde TE
Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
FASEB J Volume: 20 Page(s): 2576 - 2578
12/01/2006 Authors: Levites Y; Smithson LA; Price RW; Dakin RS; Yuan B; Sierks MR; Kim J; McGowan E; Reed DK; Rosenberry TL
Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.
J Neurosci Volume: 26 Page(s): 11923 - 11928
11/15/2006 Authors: Levites Y; Jansen K; Smithson LA; Dakin R; Holloway VM; Das P; Golde TE
Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.
J Neuroinflammation Volume: 3 Page(s): 17
07/26/2006 Authors: Das P; Smithson LA; Price RW; Holloway VM; Levites Y; Chakrabarty P; Golde TE
Devising A beta-Specific Passive Immunization Strategies for Alzheimer's Disease Using rAAV Vector-Mediated scFv Antibody Delivery
Volume: 13 Page(s): S94 - S95
05/01/2006 Authors: Fowlkes KL; Mastrangelo MA; Narrow WC; Levites Y; Golde TE; Federoff HJ; Bowers WJ
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
J Clin Invest Volume: 116 Page(s): 193 - 201
01/01/2006 Authors: Levites Y; Das P; Price RW; Rochette MJ; Kostura LA; McGowan EM; Murphy MP; Golde TE
Anti-A beta(1-16), A beta(35-40) and A beta(35-42) single-chain variable region fragments as potential therapeutic agents for AD
Volume: 25 Page(s): S573 - S573
07/01/2004 Authors: Levites Y; Das P; Golde TE
Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate.
FASEB J Volume: 17 Page(s): 952 - 954
05/01/2003 Authors: Levites Y; Amit T; Mandel S; Youdim MBH
Iron chelators-radical scavengers 3,3-epigallocatechin-3-gallate (EGCG) from tea extract and apomorphine attenuate neuronal cell death in 6-hydroxydopamine and MPTP models of Parkinson's Disease: Possible gene targets employing CDNA microarray
BIOMETALS Volume: 16 Page(s): 228 - 228
03/01/2003 Authors: Youdim MBH; Mandel S; Maor G; Levites Y
Neuroprotective strategies in Parkinson's disease : an update on progress.
CNS Drugs Volume: 17 Page(s): 729 - 762
01/01/2003 Authors: Mandel S; Grnblatt E; Riederer P; Gerlach M; Levites Y; Youdim MBH
Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology Volume: 17 Page(s): 952 - 954
01/01/2003 Authors: Levites Y; Amit T; Mandel S; Youdim MBH
Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron.
Neurotox Res Volume: 4 Page(s): 679 - 689
11/01/2002 Authors: Youdim MBH; Grnblatt E; Levites Y; Maor G; Mandel S
Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action.
J Biol Chem Volume: 277 Page(s): 30574 - 30580
08/23/2002 Authors: Levites Y; Amit T; Youdim MBH; Mandel S
C-DNA Microarray to determine molecular events in neurodegeneration and neuroprotection
Volume: 81 Page(s): 4 - 4
06/01/2002 Authors: Youdim MBH; Levites Y; Weinreb O; Mandel S
Neuroprotective actions of green tea polyphenol, (-)-epigallocatechin-3-gallate in models of Parkinson's disease: Gene targets
Volume: 53 Page(s): 463 - 466
01/01/2002 Authors: Mandel S; Levites Y; Weinreb O; Youdim MBH
A unique neuroprotective mechanism of action of green tea component (-)-epigallocatechin-3-gallate, via specific activation of protein kinase c and modulation of cell survival genes
Volume: 33 Page(s): S206 - S206
01/01/2002 Authors: Mandel S; Levites Y; Amit T; Youdim MBH
Neuroprotection/neurorescue actions and regulation of APP processing by the major green tea polyphenol, EGCG: Involvement of PKC.
Volume: 33 Page(s): S205 - S206
01/01/2002 Authors: Levites Y; Amit T; Mandel S; Youdim MBH
What can be learnt from cDNA microarray gene expression about oxidative stress in dopaminergic neuron death and Parkinson's disease?
Volume: 33 Page(s): S115 - S116
01/01/2002 Authors: Youdim MBH; Levites Y; Grunblatt E; Weinreb O; Mandel S
Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures.
Biochem Pharmacol Volume: 63 Page(s): 21 - 29
01/01/2002 Authors: Levites Y; Youdim MBH; Maor G; Mandel S
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration.
J Neurochem Volume: 78 Page(s): 1073 - 1082
09/01/2001 Authors: Levites Y; Weinreb O; Maor G; Youdim MB; Mandel S